Table 1. Baseline characteristics of the patients included in the study.
| Male, no. (%) | 48 (82.8) |
| Age, years, M (range) | 44 (27 – 57) |
| Weight, kg, M (range) | 69 (41.3 – 102.0) |
| Risk factor for HIV-HCV, no. (%) | |
| Previous injection drug use | 47 (81.0) |
| Other | 11 (18.9) |
| Previous C stage (CDC), no. (%) | 10 (17.2) |
| CD4/µl, M (range) | 395 (92 – 1500) |
| <200/µl, no. (%) | 3 (5.2) |
| HIV-RNA copies/mL, M (range) | <50 (<50 – 64200) |
| >50 copies/mL, no. (%) | 13 (22.4) |
| Antiretroviral treatment, no. (%) | 51 (87.9) |
| 2 N(t)RTIs+1 PI | 29 (50.0) |
| 2 N(t)RTIs+1 NNRTI | 16 (27.6) |
| Other | 6 (10.3) |
| HCV RNA IU/ml, M (range) | 530975 (1054 – 14085574) |
| >800000 IU/ml, no. (%) | 21 (36.2) |
| Elevated ALT, no. (%) | 48 (82.7) |
| LDL-C mg/dL, M (range) | 84 (27 – 181) |
| Fibrosis stage (biopsy or FibroScan), no. (%) | 56 (96.6) |
| F 0–1 | 26 (46.4) |
| F 2 | 6 (10.3) |
| F 3 | 3 (5.2) |
| F 4 | 21 (36.2) |
| IL-28B (rs129679860 SNP), no. (%) | 47 (78.3) |
| CC | 25 (43.1) |
| CT | 19 (32.8) |
| TT | 1 (1.7) |
M: median. N(t)RTIs: nucleos(t)ide analogue reverse transcriptase inhibitors. NNRTI: nonnucleoside reverse transcriptase inhibitor. PI: protease inhibitor. LDL-C: low-density lipoprotein cholesterol.